Qualifying Conditions

Qualifying Conditions for New York

For Adults, Debilitating Medical Conditions Include:

  • Cancer (Effective 2012)
  • Glaucoma (Effective 2012)
  • Positive Status for Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome (Effective 2012)
  • Parkinson’s Disease (Effective 2012)
  • Multiple Sclerosis (Effective 2012)
  • Damage to the Nervous Tissue of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity (Effective 2012)
  • Epilepsy (Effective 2012)
  • Cachexia (Effective 2012)
  • Wasting Syndrome (Effective 2012)
  • Crohn’s Disease (Effective 2012)
  • Post-Traumatic Stress Disorder (Effective 2012)
  • Sickle Cell Disease (Effective 2016)*
  • Post Laminectomy Syndrome with Chronic Radiculopathy (Effective 2016)*
  • Severe Psoriasis and Psoriatic Arthritis (Effective 2016)*
  • Amyotrophic Lateral Sclerosis (Effective 2016)*
  • Ulcerative Colitis (Effective 2016)*
  • Complex Regional Pain Syndrome, Type 1 and Type II (Effective 2016)*
  • Cerebral Palsy (Effective 2016)
  • Cystic Fibrosis (Effective 2016)
  • Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
  • Terminal Illness Requiring End-Of-Life Care (Effective 2016)
  • Uncontrolled Intractable Seizure Disorder (Effective 2016)
  • Spasticity or Neuropathic Pain Associated with Fibromyalgia (Effective 2018)*
  • Severe Rheumatoid Arthritis (Effective 2018)*
  • Post Herpetic Neuralgia (Effective 2018)*
  • Hydrocephalus with Intractable Headache (Effective 2018)*
  • Intractable Headache Syndromes (Effective 2018)*
  • Neuropathic Facial Pain (Effective 2018)*
  • Muscular Dystrophy (Effective 2018)*
  • Osteogenesis Imperfecta (Effective 2018)*
  • Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders (Effective 2018)*
  • Interstitial Cystitis (Effective 2019)*
  • MALS Syndrome (Median Arcuate Ligament Syndrome) (Effective 2019)*
  • Vulvodynia and Vulvar Burning (Effective 2019)*
  • Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*
  • Tourette Syndrome (Effective 2019)*
  • Chronic Pain of at least 6 months duration associated with a specified underlying chronic condition refractory to other treatment intervention (Effective 2020)*
  • Ehlers-Danlos Syndrome Associated with Chronic Pain (Effective 2020)*
  • Chronic Pancreatitis (Effective 2021)*
  • Movement disorders associated with Huntington Disease (Effective 2021)

For Patients Under 18, Debilitating Medical Conditions Include

  • Cerebral Palsy (Effective 2016)
  • Cystic Fibrosis (Effective 2016)
  • Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
  • Severe Epilepsy (Effective 2016)
  • Terminal Illness Requiring End-Of-Life Care (Effective 2016)
  • Uncontrolled Intractable Seizure Disorder (Effective 2016)
  • Muscular Dystrophy (Effective 2018)*
  • Osteogenesis Imperfecta (Effective 2018)*
  • Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*
  • Tourette Syndrome for patients who have failed standard medical treatment (Effective 2019)*
  • Chronic Pancreatitis for patients whose pain is recalcitrant to standard medical management (Effective 2021)*
ALS
Cancer
Chronic Pain
Crohn’s Disease
Epilepsy
HIV/AIDS
Huntington’s Disease
Inflammatory Bowel Disease or IBS
Multiple Sclerosis (MS)
Neuropathy
Opioid or Substance Use Disorder
Parkinson’s Disease
PTSD
Spinal Cord Injury
Any condition for which an opioid could be prescribed